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The quest to find effective treatments in glioblastoma, with the exception of one 
agent in 20 years, continues to fail. One reason is parading ineffective 
treatments as “promising” based on flawed studies. 
An underpowered randomized Phase II study of valganciclovir demonstrated 
lack of efficacy1 and yet, a biased retrospective analysis subselecting 
favourable patients gets unwarranted publicity, in the New England Journal of 
Medicine2. Improved survival is claimed for newly assembled 50 valganciclovir 
patients, consisting of 22 from the experimental arm1, 8 cross-over patients 
from the control arm1 (i.e. those that did well enough to make the cross-over), 
and 20 odd patients treated outside a trial at the same institution.2 In all patients 
valganciclovir was only given “when there was no evidence of progression” (i.e. 
good prognosis patients). These were compared with a poorly characterized 
“contemporary control” group. 
Looking at CMV as a target may be reasonable, but to demonstrate efficacy of 
anti-CMV strategies in glioblastoma needs well designed prospective studies 
avoiding claims which are potentially misleading. On current evidence there is 
no justification to expose glioblastoma patients to valganciclovir outside a 
clinical trial. 
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